Recent Refactory/Recurrent Prostate Cancer News

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (June 13, 2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy... Continue Reading

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (November 4, 2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results... Continue Reading

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer (November 6, 2014)

For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy... Continue Reading

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (September 18, 2014)

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor... Continue Reading

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer (September 15, 2014)

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine. ... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their... Continue Reading

Cabozantinib Development in Prostate Cancer Halted (September 3, 2014)

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal... Continue Reading

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer (August 27, 2014)

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA... Continue Reading

Next Page »